Drug intelligence / Profile preview

J2H-2202

Development stage: Unknown
Lead developer: J2H Biotech
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

J2H-2202 is a targeted protein degradation (TPD) drug candidate under development by J2H Biotech for the treatment of non-small cell lung cancer (NSCLC). It is designed to induce the degradation of specific disease-related proteins, leveraging the TPD modality to potentially overcome resistance mechanisms and improve therapeutic outcomes in oncology. The drug is currently in the discovery stage, with its primary indication being NSCLC. No detailed information about its molecular target or mechanism has been disclosed publicly[1][2].

Beyond the preview

Go deeper on J2H-2202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on J2H-2202.

Explore the full profile